Social cost estimates are potentially a valuable source of informing policy makers on the impact of prevention, treatment and law enforcement strategies. However, estimating the social costs of illegal drug use poses a methodological challenge, given the difficulty of quantifying the link between drugs and their negative consequences and in assigning a monetary value to items that do not have market value. This study presents methodological guidance on developing indicators to calculate the social cost of drug abuse, mainly through a "cost-of-illness" approach. The document also contains two case studies of research projects in France that have applied a social-cost analysis to the use of alcohol and tobacco, and to illicit drugs.
Alcohol, tobacco, illegal drugs and psychoactive medication (mis)use are associated with a higher likelihood of developing several diseases, (traffic) injuries and crimes. These substances reduce quality of life and increase the health care and law enforcement costs, productivity losses, etc. Consequently, the social and economic impact of substances on society is substantial. The SOCOST study estimates for the first time social costs for alcohol, tobacco, illegal drugs and psychoactive medication in Belgium for the year 2012. This cost-of-illness study presents the direct costs, the indirect cost as well as the intangible costs related to substance (mis)use. This research was commissioned by the Belgian Federal Science Policy Office (BELSPO) in the framework of the Federal Research Programme Drugs. Two universities cooperated: Ghent University, Institute for International Research on Criminal Policy (IRCP) and the Vrije Universiteit Brussel, Interuniversity Centre for Health Economics Research (I-CHER). The research was conducted under supervision of prof. dr. Freya Vander Laenen, prof. dr. Koen Putman, prof. dr. Lieven Pauwels, prof. dr. Wim Hardyns and prof. dr. Lieven Annemans.
Treating Drug Problems, Volume 2 presents a wealth of incisive and accessible information on the issue of drug abuse and treatment in America. Several papers lay bare the relationship between drug treatment and other aspects of drug policy, including a powerful overview of twentieth century narcotics use in America and a unique account of how the federal government has built and managed the drug treatment system from the 1960s to the present. Two papers focus on the criminal justice system. The remaining papers focus on Employer policies and practices toward illegal drugs. Patterns and cycles of cocaine use in subcultures and the popular culture. Drug treatment from a marketing, supply-and-demand perspective, including an analysis of policy options. Treating Drug Problems, Volume 2 provides important information to policy makers and administrators, drug treatment specialists, and researchers.
Despite efforts to reduce drug consumption in the United States over the past 35 years, drugs are just as cheap and available as they have ever been. Cocaine, heroin, and methamphetamines continue to cause great harm in the country, particularly in minority communities in the major cities. Marijuana use remains a part of adolescent development for about half of the country's young people, although there is controversy about the extent of its harm. Given the persistence of drug demand in the face of lengthy and expensive efforts to control the markets, the National Institute of Justice asked the National Research Council to undertake a study of current research on the demand for drugs in order to help better focus national efforts to reduce that demand. This study complements the 2003 book, Informing America's Policy on Illegal Drugs by giving more attention to the sources of demand and assessing the potential of demand-side interventions to make a substantial difference to the nation's drug problems. Understanding the Demand for Illegal Drugs therefore focuses tightly on demand models in the field of economics and evaluates the data needs for advancing this relatively undeveloped area of investigation.
Biomedical informatics is becoming increasingly important as healthcare organizations worldwide implement biomedical informatics applications as part of their continued effort to improve the effectiveness of patient care and the efficiency of service delivery. This book presents the full papers delivered at the 2013 International Conference on Informatics, Management and Technology in Healthcare (ICIMTH 2013), held in Athens, Greece, in July 2013. The scope of biomedical informatics is very broad, including a number of technologies such as imaging, sensors, biomedical equipment and even organ transplant technology. The 90 papers included here examine research and applications outcomes - from cell to population - in these diverse fields, and because management and organizational issues play an important role in the implementation phase of biomedical informatics applications, these topics are also covered as an integral part of the theme. The book will be of interest to all those whose work involves the development and use of biomedical informatics applications.
The impact of information technology on the management of healthcare has been enormous in recent years, and it continues to grow in scope and complexity. This book presents papers from the 2014 International Conference on Informatics, Management, and Technology in Healthcare (ICIMTH), held in Athens, Greece, in July 2014. The book includes 79 full papers and 12 poster presentations as well as keynotes, two workshops and three tutorials. Papers are divided into sections including: clinical informatics; decision support and intelligent systems; e-learning and education; health informatics, information management and technology assessment; healthcare IT; mobile technology in healthcare; public health informatics and issues; social and legal issues; and telemedicine. The book will be of interest to all those whose work involves the use of biomedical and health informatics.
The International guidelines for estimating the costs of substance abuse presents a general framework for the development of cost estimates. A matrix of the types of costs to be considered is presented and there is a detailed discussion of the theoretical issues involved including: the definition of abuse determination of causality comparison of the demographic and human capital approaches to cost estimation the treatment and measurement of addictive consumption the treatment of private costs the measurement of intangible costs the treatment of non-workforce mortality and morbidity etc. Special considerations are discussed with regard to developing economies and drug-producing countries. The guidelines conclude with a brief discussion of future directions and the implications of these guidelines to research agendas and data collection systems.
Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.
Supply reduction is often the main approach used for addressing the illicit drug problem. – Pompidou Group Evaluating drug policy is an integral part of a cost-efficient approach to tackle illicit drugs. This report takes a first step towards a systematic analysis, by examining a set of representative attempts to estimate public expenditure on supply reduction interventions. It proposes a common set of definitions, aiming to establish a common basis for understanding this topic and facilitating comparability in three main dimensions: time, policy and countries. Although it is mainly confined to supply reduction expenditures, in order to set the context, it describes the proportion that total drugrelated expenditure represents of national public spending and presents the balance between demand and supply reduction spending for a number of European countries. Finally, with the aim of facilitating and promoting future empirical expenditure studies and of setting the ground for the development of good practices, relevant data sources and methodologies applied are listed and discussed and examples of sectorial models of public spending are selectively provided.
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
